Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

Psyence Biomedical Files Prospectus Relates to Potential Offer, Sale, From Time to Time 10.9 Mln Common Shares by Selling Securityholders

This prospectus relates to the potential offer and sale, from time to time, of an aggregate of 10,882,355 common shares, no par value (“Common Shares”), of Psyence Biomedical Ltd., a corporation organized under the laws of Ontario, Canada (“Psyence,” the “Company,” “we,” “us” or “our”) by the selling securityholders named in this prospectus (each a “Selling Securityholder”), consisting of (i) 182,323 Common Shares issued to the Harraden Funds (as defined below) pursuant to the Termination Agreement, (ii) 337,750 Common Shares issued to Psyence Group Inc (“PGI” or “Parent”) pursuant to the Company’s make-whole obligations under the PGI Swap Agreements (as defined below), (iii) 257,021 Common Shares issued to PGI pursuant to the Company’s make-whole obligations under the Psylabs Purchase Agreement (as defined below), (iv) 43,080 Common Shares issued to Newcourt SPAC Sponsor LLC (the “Sponsor”) pursuant to the Company’s debt settlement obligations under the Sponsor Swap Agreement (as defined below), (v) 62,181 Common Shares issued pursuant to the Company’s make-whole obligations under the Sponsor Swap Agreements, and (vi) an aggregate of up to 10,000,000 Common Shares (the “Commitment Shares”) issuable by the Company to White Lion Capital, LLC (“White Lion”) pursuant to the White Lion Purchase Agreement (as defined below). Such Common Shares issued pursuant to the Swap Agreements are hereinafter referred to as the “Swap Shares”.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
3
+0
11
Translate
Report
3469 Views
Comment
Sign in to post a comment

View more comments...